These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21292686)

  • 1. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.
    Kunz M; Thon N; Eigenbrod S; Hartmann C; Egensperger R; Herms J; Geisler J; la Fougere C; Lutz J; Linn J; Kreth S; von Deimling A; Tonn JC; Kretzschmar HA; Pöpperl G; Kreth FW
    Neuro Oncol; 2011 Mar; 13(3):307-16. PubMed ID: 21292686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.
    Thon N; Kunz M; Lemke L; Jansen NL; Eigenbrod S; Kreth S; Lutz J; Egensperger R; Giese A; Herms J; Weller M; Kretzschmar H; Tonn JC; la Fougère C; Kreth FW
    Int J Cancer; 2015 May; 136(9):2132-45. PubMed ID: 25311315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation status shows no effect on [
    Song S; Shan Y; Wang L; Cheng Y; Yang H; Zhao G; Wang Z; Lu J
    Eur Radiol; 2022 Aug; 32(8):5577-5587. PubMed ID: 35192012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of [
    Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
    Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
    Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
    Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence.
    Ewelt C; Floeth FW; Felsberg J; Steiger HJ; Sabel M; Langen KJ; Stoffels G; Stummer W
    Clin Neurol Neurosurg; 2011 Sep; 113(7):541-7. PubMed ID: 21507562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
    Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
    Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of O-(2-[
    Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C
    Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
    Röhrich M; Huang K; Schrimpf D; Albert NL; Hielscher T; von Deimling A; Schüller U; Dimitrakopoulou-Strauss A; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1573-1584. PubMed ID: 29732524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
    Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
    J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.
    Galldiks N; Unterrainer M; Judov N; Stoffels G; Rapp M; Lohmann P; Vettermann F; Dunkl V; Suchorska B; Tonn JC; Kreth FW; Fink GR; Bartenstein P; Langen KJ; Albert NL
    Neuro Oncol; 2019 Oct; 21(10):1331-1338. PubMed ID: 31077276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
    Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
    J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
    Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
    Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
    Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
    Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas.
    Choi H; Bang JI; Cheon GJ; Kim YH; Park CK; Park SH; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2015 Mar; 36(3):211-8. PubMed ID: 25340951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.